Lupin receives six observations from the USFDA following an inspection of its Pithampur plant in Madhya Pradesh. The company is addressing the observations and will respond within the stipulated timeframe.
New Delhi, Sep 28 (PTI) Drug firm Lupin on Saturday said the US health regulator has issued six observations after inspecting its Madhya Pradesh-based manufacturing facility.
The US Food and Drug Administration (USFDA) inspected the company's Pithampur Unit-1 API and finished product manufacturing facility from September 16 to September 27, 2024, Lupin said in a regulatory filing.
The inspection closed with three observations each on the API and finished product side, it added.
"We are addressing the observations comprehensively and will respond to the US FDA within the stipulated timeframe," the Mumbai-based drug maker said.
Home » Market News » Lupin Gets USFDA Observations for Pithampur Plant
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback